Company:  NEUROCRINE BIOSCIENCES IN ... (NBIX)
Form Type:  10-K
Filing Date:  2/8/2013 
CIK:  0000914475 
Address:  12780 EL CAMINO REAL 
City, State, Zip:  SAN DIEGO, California 92130 
Telephone:  (858) 617-7600 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$13.79  
Change: 
0.01 (0.07%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$1.05B
Description of Business
We were originally incorporated in California in January 1992 and were reincorporated in Delaware in May 1996. We discover and develop innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through our novel R&D platform, focused on neurological and endocrine based diseases and disorders. Our two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women�s health that is partnered with AbbVie Inc. (AbbVie), and a wholly owned vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. We intend to maintain certain commercial rights to our VMAT2 inhibitor and evolve into a fully-integrated pharmaceutical company.
Register for EDGAR Pro and access this filing in:     
  FORM 10-K
    PART I
      ITEM 1. BUSINESS
      ITEM 1A. RISK FACTORS
      ITEM 1B. UNRESOLVED STAFF COMMENTS
      ITEM 2. PROPERTIES
      ITEM 3. LEGAL PROCEEDINGS
      ITEM 4. MINE SAFETY DISCLOSURES
    PART II
      ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED ...
      ITEM 6. SELECTED FINANCIAL DATA
        INCOME STATEMENT
      ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL ...
        Liquidity and Capital Resources
      ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT ...
      ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
        REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
        BALANCE SHEET
        STOCKHOLDERS EQUITY
        CASH FLOW
        NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
          NOTE 12. SUBSEQUENT EVENTS
      ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ...
      ITEM 9A. CONTROLS AND PROCEDURES
      Report of Independent Registered Public Accounting Firm
      ITEM 9B. OTHER INFORMATION
    PART III
      ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
      ITEM 11. EXECUTIVE COMPENSATION
      ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND ...
      ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND ...
      ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
    PART IV
      ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
    Report of Independent Registered Public Accounting Firm
    SIGNATURES
  EXHIBIT 3.1
    CERTIFICATE OF INCORPORATION
  EXHIBIT 3.2
  EXHIBIT 3.3
    BYLAWS
    3.17 SOLE DIRECTOR PROVIDED BY CERTIFICATE OF INCORPORATION
  EXHIBIT 21.1
  EXHIBIT 23.1
    Consent of Independent Registered Public Accounting Firm
  EXHIBIT 31.1
    CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT
  EXHIBIT 31.2
    CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT
  EXHIBIT 32
    CERTIFICATIONS OF
BROKERAGE PARTNERS